Loading
A phase 2 trial of Elacestrant in HR-positive / HER2-negative breast cancer, run by Stemline Therapeutics, Inc., active and no longer recruiting.
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study is a phase 2 interventional study registered as NCT05596409 by Stemline Therapeutics, Inc., with 61 participants enrolled, started 2023-05-19 and due to reach its primary completion in 2026-11. Interventions recorded: Elacestrant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/